February 16, 2017 / 7:15 AM / 6 months ago

BRIEF-Celyad registers first hematological patient in CAR-T NKR-2 THINK trial

Feb 16 (Reuters) - Celyad Sa:

* Celyad registers first hematological patient in CAR-T NKR-2 THINK trial

* No toxic events reported in patients enrolled in the solid arm of the study so far Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below